Patents by Inventor Charlotte FIELDHOUSE

Charlotte FIELDHOUSE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • H4 ANTAGONIST COMPOUNDS
    Publication number: 20230167094
    Abstract: The disclosure herein relates to azetidinylpyrimidin-2-amine derivatives, their use as Histamine H4 receptor antagonists and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with H4 receptors.
    Type: Application
    Filed: April 22, 2021
    Publication date: June 1, 2023
    Applicant: Heptares Therapeutics Limited
    Inventors: Miles Stuart CONGREVE, Charlotte FIELDHOUSE, Nigel Alan SWAIN, Mark PICKWORTH, Duncan Robert HANNAH
  • PHARMACEUTICAL COMPOUNDS
    Publication number: 20220380379
    Abstract: This invention relates to compounds that are agonists of the muscarinic M1 and M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M1 and/or M4 receptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula (1): and salts thereof.
    Type: Application
    Filed: July 27, 2022
    Publication date: December 1, 2022
    Inventors: Charlotte Fieldhouse, Miles Stuart Congreve
  • PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS
    Publication number: 20220008416
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: August 30, 2021
    Publication date: January 13, 2022
    Inventors: William FARNABY, Charlotte FIELDHOUSE, Katherine HAZEL, Catrina KERR, Natasha KINSELLA, David LIVERMORE, Kevin MERCHANT, David MILLER
  • PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS
    Publication number: 20210300906
    Abstract: The disclosures herein relate to novel compounds of formula (1): and salts thereof, wherein A; X; n; R1 and R2 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with H4 receptors.
    Type: Application
    Filed: October 21, 2019
    Publication date: September 30, 2021
    Inventors: Giles Albert Brown, Miles Stuart Congreve, Barry John Teobald, Charlotte Fieldhouse, Nigel Alan Swain, Mark Pickworth, Giovanni Bottegoni
  • Pyridazinone compounds and their use as DAAO inhibitors
    Patent number: 11129828
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: September 24, 2019
    Date of Patent: September 28, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: William Farnaby, Charlotte Fieldhouse, Katherine Hazel, Catrina Kerr, Natasha Kinsella, David Livermore, Kevin Merchant, David Miller
  • 1,2-substituted cyclopentanes as orexin receptor antagonists
    Patent number: 10689373
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein L, X, Ra, Rb, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: June 23, 2020
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Charlotte Fieldhouse, Angela Glen, Stephanie Maine, Tatsuhiko Fujimoto, John Stephen Robinson
  • PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS
    Publication number: 20200121678
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: September 24, 2019
    Publication date: April 23, 2020
    Inventors: William FARNABY, Charlotte FIELDHOUSE, Katherine HAZEL, Catrina KERR, Natasha KINSELLA, David LIVERMORE, Kevin MERCHANT, David MILLER
  • Pyridazinone compounds and their use as DAAO inhibitors
    Patent number: 10463663
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: November 5, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: William Farnaby, Charlotte Fieldhouse, Katherine Hazel, Catrina Kerr, Natasha Kinsella, David Livermore, Kevin Merchant, David Miller
  • 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS
    Publication number: 20180282309
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein L, X, Ra, Rb, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: June 1, 2018
    Publication date: October 4, 2018
    Inventors: Charlotte Fieldhouse, Angela Glen, Stephanie Maine, Tatsuhiko Fujimoto, John Stephen Robinson
  • 1,2-substituted cyclopentanes as orexin receptor antagonists
    Patent number: 10011588
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, (I) wherein L, X, Ra, Rb, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: February 19, 2015
    Date of Patent: July 3, 2018
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Charlotte Fieldhouse, Angela Glen, Stephanie Maine, Tatsuhiko Fujimoto, John Stephen Robinson
  • PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS
    Publication number: 20180177780
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: February 20, 2018
    Publication date: June 28, 2018
    Inventors: William FARNABY, Charlotte FIELDHOUSE, Katherine HAZEL, Catrina KERR, Natasha KINSELLA, David LIVERMORE, Kevin MERCHANT, David MILLER
  • Pyridazinone compounds and their use as DAAO inhibitors
    Patent number: 9931340
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy:
    Type: Grant
    Filed: February 3, 2016
    Date of Patent: April 3, 2018
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: William Farnaby, Charlotte Fieldhouse, Katherine Hazel, Catrina Kerr, Natasha Kinsella, David Livermore, Kevin Merchant, David Miller
  • Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists
    Patent number: 9790220
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, Formula (I) wherein L, X, Ra, Rb, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: February 19, 2015
    Date of Patent: October 17, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Charlotte Fieldhouse, Angela Glen, Tatsuhiko Fujimoto, John Stephen Robinson
  • Pyridazinones as DAAO enzyme inhibitors
    Patent number: 9750748
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: September 5, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: William Farnaby, Charlotte Fieldhouse, Katherine Hazel, Catrina Kerr, Natasha Kinsella, David Livermore, Kevin Merchant, David Miller
  • PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS
    Publication number: 20170173007
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: February 3, 2016
    Publication date: June 22, 2017
    Inventors: William FARNABY, CharLotte FIELDHOUSE, Katherine HAZEL, Catrina KERR, Natasha KINSELLA, David LIVERMORE, Kevin MERCHANT, David MILLER
  • SUBSTITUTED CYCLOPENTANES, TETRAHYDROFURANES AND PYRROLIDINES AS OREXIN RECEPTOR ANTAGONISTS
    Publication number: 20170073340
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, Formula (I) wherein L, X, Ra, Rb, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: February 19, 2015
    Publication date: March 16, 2017
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Charlotte Fieldhouse, Angela Glen, Tatsuhiko Fujimoto, John Stephen Robinson
  • 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS
    Publication number: 20170066744
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, (I) wherein L, X, Ra, Rb, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: February 19, 2015
    Publication date: March 9, 2017
    Inventors: Charlotte Fieldhouse, Angela Glen, Stephanie Maine, Tatsuhiko Fujimoto, John Stephen Robinson
  • Cyclopentylbenzamide derivatives and their use for the treatment of psychotic and cognitive disorders
    Patent number: 9493432
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein n, L, X, Ra, Rb, R1, R2 and R3 their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: November 15, 2016
    Assignee: Takeda Pharmaceuticals Company Limited
    Inventors: Charlotte Fieldhouse, Angela Glen, John Stephen Robinson, Tatsuhiko Fujimoto
  • Cyclopentylbenzamide Derivatives and their Use for the Treatment of Psychotic and Cognitive Disorders
    Publication number: 20160222030
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein n, L, X, Ra, Rb, R1, R2 and R3 their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: October 14, 2014
    Publication date: August 4, 2016
    Inventors: Charlotte Fieldhouse, Angela Glen, John Stephen Robinson, Tatsuhiko Fujimoto
  • Pyridazinone compounds and their use as DAAO inhibitors
    Patent number: 9290456
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: August 21, 2012
    Date of Patent: March 22, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: William Farnaby, Charlotte Fieldhouse, Katherine Hazel, Catrina Kerr, Natasha Kinsella, David Livermore, Kevin Merchant, David Miller